Literature DB >> 9223495

Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.

S Lee1, K Peden, D S Dimitrov, C C Broder, J Manischewitz, G Denisova, J M Gershoni, H Golding.   

Abstract

The entry of human immunodeficiency virus type 1 (HIV-1) into cells is initiated by binding of the viral glycoprotein gp120-gp41 to its cellular receptor CD4. The gp120-CD4 complex formed at the cell surface undergoes conformational changes that may allow its association with an additional membrane component(s) and the eventual formation of the fusion complex. These conformational rearrangements are accompanied by immunological changes manifested by altered reactivity with monoclonal antibodies specific for the individual components and presentation of new epitopes unique to the postbinding complex. In order to analyze the structure and function of the gp120-CD4 complex, monoclonal antibodies were generated from splenocytes of BALB/c mice immunized with soluble CD4-gp120 (IIIB) molecules (J. M. Gershoni, G. Denisova, D. Raviv, N. I. Smorodinsky, and D. Buyaner, FASEB J. 7:1185-1187 1993). One of those monoclonal antibodies, CG10, was found to be strictly complex specific. Here we demonstrate that this monoclonal antibody can significantly enhance the fusion of CD4+ cells with effector cells expressing multiple HIV-1 envelopes. Both T-cell-line-tropic and macrophage-tropic envelope-mediated cell fusion were enhanced, albeit at different optimal doses. Furthermore, infection of HeLa CD4+ (MAGI) cells by HIV-1 LAI, ELI1, and ELI2 strains was increased two- to fourfold in the presence of CG10 monoclonal antibodies, suggesting an effect on viral entry. These findings indicate the existence of a novel, conserved CD4-gp120 intermediate structure that plays an important role in HIV-1 cell fusion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223495      PMCID: PMC191861     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  P L Earl; S Koenig; B Moss
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

2.  Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells.

Authors:  P A Ashorn; E A Berger; B Moss
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI.

Authors:  K Peden; M Emerman; L Montagnier
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

4.  Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120.

Authors:  N C Sun; D D Ho; C R Sun; R S Liou; W Gordon; M S Fung; X L Li; R C Ting; T H Lee; N T Chang
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

5.  Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4.

Authors:  P Bedinger; A Moriarty; R C von Borstel; N J Donovan; K S Steimer; D R Littman
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

6.  The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s).

Authors:  C C Broder; D S Dimitrov; R Blumenthal; E A Berger
Journal:  Virology       Date:  1993-03       Impact factor: 3.616

7.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

8.  Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding.

Authors:  F Celada; C Cambiaggi; J Maccari; S Burastero; T Gregory; E Patzer; J Porter; C McDanal; T Matthews
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

9.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

10.  Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.

Authors:  D Healey; L Dianda; J P Moore; J S McDougal; M J Moore; P Estess; D Buck; P D Kwong; P C Beverley; Q J Sattentau
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more
  10 in total

1.  Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.

Authors:  Gilad Kaplan; Anna Roitburd-Berman; George K Lewis; Jonathan M Gershoni
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Reduced monomeric CD4 is the preferred receptor for HIV.

Authors:  Lisa J Matthias; Iman Azimi; Catherine A Tabrett; Philip J Hogg
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

3.  Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion.

Authors:  Janet E Lineberger; Renee Danzeisen; Daria J Hazuda; Adam J Simon; Michael D Miller
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.

Authors:  Syna Kuriakose Gift; Isaac J Zentner; Arne Schön; Karyn McFadden; M Umashankara; Srivats Rajagopal; Mark Contarino; Caitlin Duffy; Joel R Courter; Mei-Yun Zhang; Jonathan M Gershoni; Simon Cocklin; Dimiter S Dimitrov; Amos B Smith; Ernesto Freire; Irwin M Chaiken
Journal:  Biochemistry       Date:  2011-03-18       Impact factor: 3.162

5.  Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion.

Authors:  C M Finnegan; W Berg; G K Lewis; A L DeVico
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.

Authors:  N Sullivan; Y Sun; Q Sattentau; M Thali; D Wu; G Denisova; J Gershoni; J Robinson; J Moore; J Sodroski
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

8.  Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.

Authors:  Gerald V Quinnan; Olusegun Onabajo; Pengfei Zhang; Lianying Yan; Joseph J Mattapallil; Zhiqiang Zhang; Ming Dong; Min Lu; David Montefiori; Celia LaBranche; Christopher C Broder
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

9.  In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells.

Authors:  Masaru Yokoyama; Masako Nomaguchi; Naoya Doi; Tadahito Kanda; Akio Adachi; Hironori Sato
Journal:  Front Microbiol       Date:  2016-02-09       Impact factor: 5.640

10.  Allosteric induction of the CD4-bound conformation of HIV-1 Gp120.

Authors:  Anna Roitburd-Berman; Gal Dela; Gilad Kaplan; George K Lewis; Jonathan M Gershoni
Journal:  Retrovirology       Date:  2013-12-05       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.